← All trials
NCT04604899
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2020
- Primary completion
- Feb 28, 2022
- Completion date
- Apr 30, 2022
- First posted
- Oct 27, 2020
- Last posted
- Nov 17, 2020
- Enrollment
- 30
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- jCyte, IncLead sponsor
- California Institute for Regenerative Medicine (CIRM)Collaborator
- University of California, IrvineOverall official - principal investigator
- Retina-Vitreous Associates Medical GroupOverall official - principal investigator
- Ophthalmic Consultants of BostonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.